Veklury (Remdesivir) Patent Expiration, LOE Window & CMS Spending
Veklury (Remdesivir) by Gilead Sciences: FDA Orange Book core substance LOE 2036-04-29 (last listed 2041-11-28), 0 AB generics, $2.7M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Gilead Sciences |
| FDA Application & Pathway | N214787 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2036-04-29 |
| Last Listed Patent or Exclusivity Date | 2041-11-28 |
| Orange Book Patents (*PED Extensions) | 32 patents (16 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $2.7M |
| 2024 Medicare Part D Spend | $381K |
| 2024 Medicaid Spend | $2.3M |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 18.2% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.